Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Clear all
Completed Phase 1 Interventional

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

NCT01019603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene, Tazaroc Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea

NCT05014906
View directory record Official record
Conditions
Rosacea
Interventions
Minocycline 45 MG, Azelaic acid
Drug
Lead sponsor
Dermatology Specialists Research
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Fremont, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Intralesional Injections of Triamcinolone for Acne Vulgaris

NCT06170593
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Triamcinolone Injection
Drug
Lead sponsor
ACOM Labs
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Ultherapy® for the Treatment of Acne Scars

NCT02145364
View directory record Official record
Conditions
Acne Scars, Atrophic Acne Scars
Interventions
Ultherapy® treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Beverly Hills, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

NCT02682264
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01 cream, 1%
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
39
States / cities
Fort Smith, Arkansas • Little Rock, Arkansas • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 21, 2026, 3:17 AM EDT
Terminated No phase listed Observational

Hidradenitis - an Analysis of Genetic Traits and Linkages in Families

NCT05710393
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
7 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne

NCT02998671
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CJM112, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Culver City, California • Sacramento, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Not applicable Interventional Results available

A Novel Method to Improve Acne Outcomes

NCT01176955
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Internet survey, Benzoyl peroxide 5% gel
Behavioral · Drug
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 3:17 AM EDT
Not listed Phase 2 Interventional

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00098358
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Zileuton
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

NCT04019041
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
Interventions
bermekimab, placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Gilbert, Arizona • Huntington Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 21, 2026, 3:17 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

NCT02796066
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Vehicle, TSN2898
Drug
Lead sponsor
Thesan Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
San Diego, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 21, 2026, 3:17 AM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 3:17 AM EDT
Not listed Not applicable Interventional

A Post Market Device Study for the Treatment of Acne

NCT06469398
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Cutera Laser System
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boca Raton, Florida • Hackensack, New Jersey • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

NCT02431052
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
28
States / cities
Mobile, Alabama • Encino, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

NCT01320033
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD2475/101 40 mg, Doxycycline 100 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

NCT00673933
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Methyl aminolevulinate (MAL) PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
15 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Naperville, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 21, 2026, 3:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Almond Supplementation on Mild to Moderate Acne

NCT05269641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Food: whole almonds, Food: non-nut snack
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
15 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

NCT00663286
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-110, Clindamycin, Benzoyl peroxide, Vehicle
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
12 Years to 70 Years
Enrollment
1,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
33
States / cities
Hot Springs, Arkansas • New Haven, Connecticut • Hockessin, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Not applicable Interventional Results available

Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris

NCT00558831
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl Peroxide, Moisturizing Lotion
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 21, 2026, 3:17 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris

NCT02924428
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Venus Versa
Device
Lead sponsor
Venus Concept
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

NCT00714454
View directory record Official record
Conditions
Acne Vulgaris
Interventions
APS Topical Lotion, Placebo
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2008 · Synced Oct 21, 2026, 3:17 AM EDT
Not listed Not applicable Interventional

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

NCT02759900
View directory record Official record
Conditions
Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea, Molluscum Contagiosum, Bowen's Disease, Warts
Interventions
Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 21, 2026, 3:17 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 21, 2026, 3:17 AM EDT